We went to the U.S. Patent & Trademark Office to get the lowdown on the CRISPR gene-editing patent dispute. Read C&EN’s coverage here: [ Ссылка ]
↓↓Full description and references below↓↓
CRISPR/Cas9 is making gene-editing cheaper and easier than ever before, but the creators are embroiled in a fierce dispute over who holds the patents to CRISPR technology. In this episode, after hearing attorneys duke it out, Ryan Cross explains how the kerfuffle developed, and what the possible outcomes of the impending decision mean.
If this episode makes you crazy for more CRISPR, check out these great resources.
Expanding CRISPR toolkit may render patent fight moot | C&EN
[ Ссылка ]
The CRISPR craze continued | C&EN
[ Ссылка ]
Genome Editing Writ Large | C&EN
[ Ссылка ]
A simple guide to CRISPR, one of the biggest science stories of 2016 | Vox
[ Ссылка ]
The unsung heroes of CRISPR | Nature
[ Ссылка ]
One of our reporters tried to do CRISPR. He failed miserably. | Science
[ Ссылка ]
Who Owns the Biggest Biotech Discovery of the Century? | MIT Technology Review
[ Ссылка ]
Want even more Speaking of Chemistry?
Like us on Facebook: [ Ссылка ]
And drop us a line at speakingofchem@acs.org
Speaking of Chemistry is brought to you by Chemical & Engineering News, the news magazine of the American Chemical Society.
Find us on all these places:
Subscribe! [ Ссылка ]
Facebook! [ Ссылка ]
Twitter! [ Ссылка ]
Tumblr! [ Ссылка ]
